Jiangsu Hengrui Pharma

News

Novo turns to Hengrui for another oral obesity drug

Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.

News

Hengrui gets world-first okay for platelet drug hetrombopag

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

News

Bristol Myers Squibb and Hengrui Pharma logos

BMS signs $15.2bn R&D alliance with China's Hengrui

Hengrui agrees a $15.2bn R&D alliance with BMS in oncology/haematology and immunology, less than a year after a similar $12bn deal with GSK.

News

Obesity-focused biotech Kailera joins IPO queue in US

Kailera Therapeutics has filed for an IPO, hoping to whet investor appetites with its pipeline of drug candidates for weight loss.

News

Kailera, Hengrui stake claim to oral weight loss category

Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.

News

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Hengrui has achieved a milestone in oncology as retlirafusp alfa is approved in China, its first world market, for gastric cancer.

Novo turns to Hengrui for another oral obesity drug

Hengrui gets world-first okay for platelet drug hetrombopag

BMS signs $15.2bn R&D alliance with China's Hengrui

Obesity-focused biotech Kailera joins IPO queue in US

Kailera, Hengrui stake claim to oral weight loss category

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Jiangsu Hengrui Pharma

Editor's Picks